InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,982.40
(
-1.17%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.26
(
-0.02%
)
Bitcoin
61,326.94
(
1.77%
)
Post# of 252337
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119911
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 186912

Monday, 02/02/2015 12:06:34 PM

Monday, February 02, 2015 12:06:34 PM

Post# of 252337

…not sure why ABBV didn't PR the [GIFT-1] cirrhotic data…

All cirrhotic patients were in an open-label trial arm (arm “C” in the clinicaltrials.gov listing at https://clinicaltrials.gov/ct2/show/NCT02023099 ) that was independent from the predefined primary endpoint of the trial. The cirrhotic data will presumably be reported when the detailed data are at presented at a medical conference.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up